FERS | Jotup

EQS-News: AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Retrieved on:

Wednesday, March 13, 2024

Bronchiectasis, American Journal, Pulmonology, Asthma, AAT, European Respiratory Society, FERS, GOLD, Patient, Chronic obstructive pulmonary disease, Global Initiative, German Respiratory Society, Critical Care Medicine (journal), COPD, Pharmaceutical industry

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board

Key Points:

AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
The issuer is solely responsible for the content of this announcement.
AATec Medical appoints Professor Dr. Claus Franz Vogelmeier to the Scientific Advisory Board
Leading pulmonology expert contributes profound clinical experience in inflammatory lung diseases such as bronchiectasis, COPD, asthma, and ARDS to AATec Medical.
Munich, Germany – 29.02.2024 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform technology based on recombinant alpha-1 antitrypsin (AAT), today announced the appointment of Prof. Dr. Claus Franz Vogelmeier, Professor of Medicine and Head of the Department of Pulmonary Medicine at Philipps-University in Marburg, Germany to its Scientific Advisory Board.
Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, commented: “We are very pleased to welcome Professor Vogelmeier to our Scientific Advisory Board.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on:

Monday, November 20, 2023

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Key Points:

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
For the twelve months ended September 30, 2023, total revenue was $79.2 million compared to $86.2 million for the same period in 2022.
The decrease in the quarter and in year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.
Non-cash interest expense was $3.2 million for the three months ended September 30, 2023 and $5.1 million for the twelve months ended September 30, 2023.

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Retrieved on:

Friday, October 13, 2023

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.

Key Points:

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event to discuss advances in the treatment landscape for RSV with global experts and highlight the company’s RSV pipeline.
The event will feature presentations and discussions with:
Jamie Fergie, MD, FAAP, FIDSA, FSHEA – Medical Director, Global Institute for Hispanic Health, Professor of Pediatrics, Texas A&M University and Director, Infectious Diseases, Driscoll Children’s Hospital
Tom Wilkinson, MA (Cantab), MBBS, PhD, FRCP, FERS – Professor of Respiratory Medicine and Associate Dean, University of Southampton and Faculty of Medicine, Southampton General Hospital
The event will be led by Jay R. Luly, PhD, President and Chief Executive Officer of Enanta, who will be joined by Scott T. Rottinghaus, MD, Senior Vice President and Chief Medical Officer, and John DeVincenzo, MD, Vice President of Translational Virology.
Event details are as follows:
A webcast of the event will be available on the investor relations page of the Enanta Pharmaceuticals website at https://ir.enanta.com/events-presentations .
A replay of the webcast will be archived on Enanta’s website for at least 30 days following the presentation.

Federal Employee Benefits Training For Retirement Planning Announced By PSRE

Retrieved on:

Saturday, July 8, 2023

FERS, Learning, TSP, Federal Retirement Thrift Investment Board, FEGLI, Retirement, CSRS, Consultant, Nursing

Public Sector Retirement Educators (PSRE) is now offering web-based training courses for federal employees who want to maximize their retirement benefits.

Key Points:

To view an enhanced version of this graphic, please visit:
Federal employees seeking a more personalized and convenient approach to retirement training can now take advantage of the updated web-based retirement training courses.
PSRE recognizes the importance of retirement planning and offers expertassistance to help individuals prepare for their future and make informedfinancial decisions.
The web-based federal retirement training courses can be accessed via the organization's ADA-compliant e-learning platform or web-based federal retirement software.
For more, visit Federal Retirement FAQs
A spokesperson for the company said, "Public Sector Retirement Educators are some of the most qualified benefits experts in the country.

ISHLT Names Prof. Dirk Van Raemdonck as Inaugural Editor-in-Chief for JHLT Open

Retrieved on:

Wednesday, May 31, 2023

Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) announces the appointment of Dirk Van Raemdonck, MD, PhD, FEBTS, FERS, as the inaugural Editor-in-Chief of JHLT Open, the Society’s new open access journal.

Key Points:

Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The International Society for Heart and Lung Transplantation (ISHLT) announces the appointment of Dirk Van Raemdonck, MD, PhD, FEBTS, FERS, as the inaugural Editor-in-Chief of JHLT Open, the Society’s new open access journal.
JHLT Open is a new journal complementing the venerable Journal of Heart and Lung Transplantation (JHLT), ISHLT’s flagship journal, which is ranked as the number one journal in transplantation by impact factor.
"I am deeply honored to be appointed as the Editor-in-Chief for JHLT Open," said Prof. Van Raemdonck.
While JHLT Open will be general in content, it will also create opportunities for special virtual issues and programs that highlight specific areas of interest.

U.S. Postal Service Reports First Quarter Fiscal Year 2023 Results

Retrieved on:

Thursday, February 9, 2023

FERS, CSRS, Civil Service Retirement System, Marketing, Postal Service Reform Act of 2022, Ageing, PSRA, United States Postal Service, Louis DeJoy, Federal Employees Retirement System, COVID-19, Mail, Transport, Video game, Insurance, Cryptocurrency

Postal Service today announced its financial results for the first quarter of fiscal year 2023 (Oct. 1, 2022 - Dec. 31, 2022).

Key Points:

Postal Service today announced its financial results for the first quarter of fiscal year 2023 (Oct. 1, 2022 - Dec. 31, 2022).
The Postal Service's operating revenue was $21.5 billion for the quarter, an increase of $206 million, or 1.0 percent, on a volume decline of 1.7 billion pieces, or 4.8 percent, compared to the same quarter last year.
Shipping and Packages revenue increased $203 million, or 2.4 percent, on a volume decline of 70 million pieces, or 3.5 percent, compared to the same quarter last year.
The Postal Service's operating expenses decreased $129 million, or 0.6 percent, compared to the same quarter last year.

Public Sector Retirement Educators Launch FERS Planning & Training Platform

Retrieved on:

Sunday, September 11, 2022

Thrift Savings Plan, Retirement, Curriculum, Life, Public, Disability, Federal Employees Retirement System, FERS, Strategic planning, Pension fund, Tutoring, Financial adviser

Public Sector Retirement Educators has launched an ADA-compliant online platform that provides federal employees, at all levels of government, with remote retirement training alongside various acclaimed resources.

Key Points:

Scottsdale, Arizona--(Newsfile Corp. - September 11, 2022) - Public Sector Retirement Educators (PSRE) launched a FERS retirement training platform, as part of its mission to educate federal employees on how they can live a more fulfilled life in retirement.
Public Sector Retirement Educators' team of federal retirement advisors provides comprehensive resources on pre-retirement planning through training sessions and expertly-crafted learning material.
With the latest launch, Public Sector Retirement Educators provides a range of educational materials and delivers training on retirement planning to federal employees and federal agencies throughout the US.
A spokesperson said, "At Public Sector Retirement Educators, we offer web-based training in several formats to meet the needs of retired federal employees.

IDC FERS Survey Identifies Cybersecurity as a Top Investment Priority in the Future of Industry Ecosystems

Retrieved on:

Tuesday, January 25, 2022

In contrast, only 28% and 32% of respondents in EMEA and Asia/Pacific identified cybersecurity as a top investment area.

Key Points:

In contrast, only 28% and 32% of respondents in EMEA and Asia/Pacific identified cybersecurity as a top investment area.
In North America, only 13% of respondents identified AI/ML as an investment priority; survey results in Asia/Pacific (15%) and EMEA (19%) were similar.
"We are still in a version 1.0 phase of IT investment for the future of industry ecosystems," said Jeffrey Hojlo , research vice president, Future of Industry Ecosystems & Product Innovation Strategies.
The IDC report, Top IT Investments for Industry Ecosystems by Global Region (IDC #US48408921), provides additional detail and context about the FERS survey data on investment priorities for industry ecosystems.

IDC Future Enterprise Resiliency and Spending Survey Highlights Key Findings in the Areas of Customer Experience, Enterprise Intelligence, and Digital Sovereignty

Retrieved on:

Wednesday, October 20, 2021

Recent results from the International Data Corporation ( IDC ) Future Enterprise Resiliency and Spending (FERS) survey shed light on several key areas of digital transformation.

Key Points:

Recent results from the International Data Corporation ( IDC ) Future Enterprise Resiliency and Spending (FERS) survey shed light on several key areas of digital transformation.
Future of Customers and Consumers: Customer Experience
According to the FERS survey data, improving the customer experience (CX) directly impacts the organization's bottom line.
Companies reporting improved customer experience pointed to their efforts to reduce customer pain points (22%) and friction in customer engagement (19).
The FERS survey provides overwhelming evidence that technology and knowledge of customer data are critical in how organizations deliver customer experience.

OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia

Retrieved on:

Wednesday, September 15, 2021

ROCKVILLE, Md., Sept. 15, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced clinical data from an investigator-initiated and driven prospective randomized controlled multicenter study. Data on the Unyvero HPN was presented at the virtual European Respiratory Society (ERS) conference on September 7, 2021, and subsequently presented during a webinar held on September 14, 2021.

Key Points:

described the study which assessed the clinical utility and impact of the Unyvero panel in hospitalized adult patients with suspicion of pneumonia and a clinical indication for bronchoscopy and at risk for infection with Gram-negative bacteria.
Within 4 hours after bronchoscopy Unyvero results were available and shared with the attending physician treating the patients in the intervention group.
Faranak Atrzadeh, OpGens Chief Marketing and Scientific Affairs Officer commented: This multicenter randomized interventional study clearly demonstrates the clinical utility and actionable impact of the Unyvero HPN panel.
This press release includes statements regarding the clinical utility of the Unyvero Hospitalized Pneumonia panel based on the results of studies conducted by independent infectious disease professionals.